Deciduous tooth pulp stem cell culture system without fetal calf serum and application of deciduous tooth pulp stem cell culture system

By using low-dose human serum and concentrated growth factors to replace fetal bovine serum in the dental tooth stem cell culture system, the ethical disputes and safety of fetal bovine serum were solved, and the safety and ethical in vitro expansion of dental tooth stem cells were achieved. and clinical applications.

CN119020280AActive Publication Date: 2024-11-26HOSPITAL OF STOMATOLOGY GUANGZHOU MEDICAL UNIVERSITY (YANGCHENG HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY)
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411380662.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-30
Publication Date
2024-11-26
Estimated Expiration
2044-09-30

AI Technical Summary

Technical Problem

In the prior art, fetal bovine serum (FBS) has ethical disputes, safety issues and high cost issues in stem cell culture, and it is difficult to effectively replace it as a safe and less ethical disputed alternative, affecting the in vitro expansion of deciduous tooth stem cells and Clinical application.

Method used

Low-dose human serum (4.5-5.5%) and concentrated growth factor (CGF) were used to replace fetal bovine serum as additive ingredients in the deciduous tooth stem cell culture system to promote cell proliferation and differentiation and ensure safety and ethics.

Benefits of technology

The safe and ethical in vitro expansion of deciduous tooth stem cells was achieved, reducing the impact of exogenous factors on stem cells, and promoting their expansion to clinical scale without affecting stemness.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119020280A_ABST
    Figure CN119020280A_ABST
Patent Text Reader

Abstract

The invention discloses a deciduous tooth pulp stem cell culture system without fetal calf serum and application of the deciduous tooth pulp stem cell culture system. According to the culture medium, fetal calf serum is replaced by low-dose human serum, the human serum is added into the basic culture medium to culture the deciduous tooth pulp stem cells, and proliferation of the deciduous tooth pulp stem cells is not inhibited in the culture process. According to the present invention, the CGF is further added to be combined with the HS so as to be adopted as the FBS substitute in the conventional stem cell culture medium, the low-concentration HS and the low-concentration CGF replace the FBS so as to promote the in vitro proliferation and differentiation of the SHED, and the sufficient CGF can be extracted to amplify the SHED without the extraction of a large amount of blood; therefore, the invention provides an FBS substitute which is derived from a human body, high in safety and less in ethical dispute, exogenous factors in an SHED culture system are completely removed, the influence of external factors contained in the FBS on SHED in-vitro amplification is eliminated, and the SHED is expanded to a clinical scale under the condition that the dryness of the SHED is not influenced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and more specifically, relates to a fetal bovine serum-free deciduous tooth dental pulp stem cell culture system and application thereof. Background Art

[0002] Regenerative medicine using bone tissue engineering aims to restore the structure and function of damaged bone tissue. Bone tissue regeneration requires three basic components, namely stem cells, bioactive molecules and scaffolds. Stem cells, such as mesenchymal stem cells (MSCs), can differentiate into various cell types, such as osteoblasts, chondrocytes and myoblasts. By utilizing specific growth factors and culture conditions, MSCs have been widely studied as seed cells in cell therapy, which includes replacing dysfunctional or dead cells to restore specific body functions. In addition, under the stimulation of inflammation or chemokines (such as Vascular Endothelial Growth Factor (VEGF) or Hepatocyte Growth Factor (HGF)), MSCs show "homing" characteristics, that is, migrating to the injury site, making them a potential tool for stem cell therapy in spinal cord injury. As mesenchymal stem cells isolated from exfoliated deciduous teeth, deciduous dental pulp stem cells (SHED) have the characteristics of less ethical controversy and low immunogenicity. SHEDs have the potential for self-renewal and multidirectional differentiation, and have a higher level of stemness compared to mature dental pulp stem cells (DPSCs). Therefore, SHEDs are very promising in stem cell therapy for various diseases, such as bone tissue engineering. However, since SHEDs are relatively rare in adult tissues, it takes several weeks of in vitro expansion to produce sufficient numbers of SHEDs for clinical applications. In addition, since the inherent characteristics of stem cells, such as proliferation and differentiation, may change in vitro, special care is required to ensure the safety and regenerative efficacy of pre-cultured SHEDs when used in vivo.

[0003] Fetal bovine serum (FBS) is a universal standard component in stem cell culture media. FBS facilitates in vitro cell growth because it contains hormones (e.g., cortisol, insulin, growth hormone), proteins (e.g., albumin, globulin), growth factors (e.g., epidermal growth factor, fibroblast growth factor), lipids (e.g., endotoxins), inorganic substances, and some undefined small molecules that are directly involved in cell adhesion and growth. However, FBS has obvious disadvantages as a culture medium supplement. First, the composition and quality of FBS vary from serum batch to serum batch, which may hinder the reproducibility of experimental data. In addition, the chemical properties of FBS have not been clearly defined. Second, FBS is a xenobiotic substance in human medicine. Third, the risk of contamination by endotoxins, viruses, and prions after heat inactivation of FBS remains high. Therefore, the safety of FBS in clinical applications is controversial and it is not suitable for in vitro cell expansion before clinical application. Fourth, the FBS collection method is subject to ethical controversy. Based on these major negative factors, the present invention aims to find an FBS substitute that is derived from the human body, has high safety, and has less ethical controversy, so as to eliminate the influence of external factors (such as endotoxins and heterologous proteins) contained in FBS for SHED in vitro amplification.

[0004] Human serum (HS) has been suggested as a substitute for FBS. However, the inhibitory effect of HS on MSC proliferation has been confirmed in some studies. When 10% allogeneic HS was supplemented in the cell expansion system, the proliferation rate of bone marrow-derived MSCs decreased and the time required for cells to reach fusion was prolonged compared with the culture system supplemented with 10% FBS. In addition, the same inhibitory metabolic effect was observed in MSCs cultured with 5% or 7.5% HS (allogeneic / autologous). Although 15% HS has been used to replace fetal bovine serum in the culture system for the culture of dental pulp stem cells, the high HS dosage in practical applications generates greater costs and pressures in order to culture stem cells to a clinically applicable scale. Therefore, it is urgent to provide a low-dose FBS substitute that is derived from the human body, has high safety, and has less ethical controversy, so as to eliminate the influence of external factors (such as endotoxins and heterologous proteins) contained in FBS for SHED in vitro expansion, so that SHED can be expanded to a clinical scale without affecting its stemness. Summary of the invention

[0005] The purpose of the present invention is to overcome the above-mentioned defects and shortcomings in the prior art and to provide a culture system of deciduous tooth dental pulp stem cells that does not contain fetal bovine serum.

[0006] The second object of the present invention is to provide an application of the deciduous tooth dental pulp stem cell culture system.

[0007] The above-mentioned object of the present invention is achieved through the following technical solutions:

[0008] The invention provides a fetal bovine serum-free culture system of stem cells from human exfoliated deciduous teeth (SHED), comprising a basal culture medium and an additive component; the additive component is 4.5-5.5% human serum (HS) and 0.002-0.008 g / mL concentrated growth factor (CGF) in a volume fraction of the basal culture medium.

[0009] Among them, concentrated growth factor (CGF) is a third-generation platelet concentrate (PC), which is a fibrin biomaterial rich in growth factors. It is obtained by centrifuging autologous blood at alternating speeds without adding other substances (such as anticoagulants). CGF is a cytokine library containing high concentrations of growth factors, such as platelet-derived growth factor (PDGF), transforming growth factor β-1 (TGF-β1), insulin-like growth factor-1 (IGF-1), VEGF and fibroblast growth factor (FGF). These growth factors are closely involved in the regulation of cell proliferation, differentiation and angiogenesis, which are essential for hard and soft tissue regeneration.

[0010] Deciduous tooth pulp stem cells (SHED) are mesenchymal stem cells with self-renewal and multidirectional differentiation capabilities, but their proliferation and differentiation capabilities are insufficient for large-scale application in bone tissue engineering. In order to expand SHED to a clinical application scale, it is usually pre-cultured with fetal bovine serum (FBS). However, when SHED is transplanted into the human body, this pre-culture method may bring potential contamination or increase the risk of changing the vitality and growth of stem cells. The present invention achieves the replacement of fetal bovine serum with low-dose (4.5-5.5%) human serum, which is added to the basal culture medium to culture deciduous tooth pulp stem cells. During the culture process, there is no inhibitory effect on the proliferation of deciduous tooth pulp stem cells. Low-dose human serum also has the effect of significantly enhancing the osteogenic differentiation potential of SHED. Further adding CGF, combined with HS, as a substitute for FBS in conventional stem cell culture medium, low concentrations of HS and CGF replacing FBS can promote SHED proliferation and differentiation in vitro, and sufficient CGF can be extracted to expand SHED without extracting a large amount of blood. The present invention provides an FBS substitute that is derived from the human body, has high safety, and has less ethical controversy, completely eliminates exogenous factors in the SHED culture system, and eliminates the influence of external factors (such as endotoxins and heterologous proteins) contained in FBS on the in vitro expansion of SHED.

[0011] Furthermore, the added components are 5% human serum and 0.002-0.008 g / mL concentrated growth factor in the volume fraction of the basic culture medium.

[0012] Preferably, the added components are 5% human serum and 0.002 g / mL concentrated growth factor in the volume fraction of the basal culture medium.

[0013] Preferably, the preparation method of the concentrated growth factor CGF is to obtain a serum layer, a gelatinous CGF layer and a red blood cell layer from top to bottom after centrifuging venous blood; remove excess liquid from the CGF layer to obtain a CGF membrane, and then freeze-dry it.

[0014] Furthermore, the basal culture medium is DMEM-high glucose culture medium.

[0015] Furthermore, the deciduous tooth dental pulp stem cell culture system also contains antibiotics.

[0016] Preferably, the antibiotic is penicillin and / or streptomycin.

[0017] The present invention provides the use of any of the above-mentioned deciduous tooth dental pulp stem cell culture systems in the in vitro proliferation of deciduous tooth dental pulp stem cells.

[0018] The present invention provides the use of any of the above-mentioned deciduous tooth dental pulp stem cell culture systems in inducing differentiation of deciduous tooth dental pulp stem cells in vitro.

[0019] Furthermore, the differentiation is one or more of osteogenic differentiation, adipogenic differentiation or chondrogenic differentiation.

[0020] The present invention also provides a method for culturing deciduous tooth dental pulp stem cells, which is carried out using any of the above-mentioned deciduous tooth dental pulp stem cell culture systems.

[0021] Furthermore, the culture is proliferation culture or induced differentiation culture.

[0022] Compared with the prior art, the present invention has the following beneficial effects:

[0023] The present invention provides a culture system of deciduous dental pulp stem cells without fetal bovine serum, comprising a basic culture medium and an added component; the added component is 4.5-5.5% human serum and 0.002-0.008g / mL concentrated growth factor accounting for the volume fraction of the basic culture medium. The present invention realizes the replacement of fetal bovine serum with low-dose human serum, which is added to the basic culture medium to culture deciduous dental pulp stem cells, and has no inhibitory effect on the proliferation of deciduous dental pulp stem cells during the culture process. CGF is further added and combined with HS as a substitute for FBS in conventional stem cell culture medium. Low concentrations of HS and CGF replace FBS to promote SHED in vitro proliferation and differentiation, and sufficient CGF can be extracted to expand SHED without extracting a large amount of blood. Therefore, the present invention provides a FBS substitute derived from the human body, with high safety and less ethical controversy, which completely eliminates exogenous factors in the SHED culture system, eliminates the influence of external factors (such as endotoxins and heterologous proteins) contained in FBS on the in vitro expansion of SHED, and enables SHED to be expanded to clinical scale without affecting its stemness. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 The graph shows the effect of conditioned medium containing CGF (2×, 4×, 8×) on stimulating SHED proliferation on days 1, 3, 5 and 7; “*” indicates a significant difference compared with 10% FBS, p<0.05.

[0025] Figure 2 Figures show the cell colony morphology (A) and colony cell number (B) after SHED was cultured in a basal medium containing 5% HS or 5% HS+2×CGF for 10 days.

[0026] Figure 3The effect of 2×CGF on the migration of SHED cells; A is the crystal violet staining of migrating cells from different groups after culture in 10% FBS, 5% HS medium with or without 2×CGF for 24 h; B is the statistical analysis of the average number of migrating cells in each field of view from different groups at the 24 h time point, n=9, "*" indicates p<0.05; C is the image of scratch healing in 10% FBS, 5% HS medium with or without 2×CGF; D is the quantitative analysis of the scratch healing area using ImageJ software, scale bar=200μm, "*" indicates a significant difference compared with the 10% FBS group, p<0.05.

[0027] Figure 4 ALP staining (A) and quantification (B) results of SHED stimulated with osteogenic medium containing CGF (2×, 4×, 8×) on days 4 and 7; "*" indicates p<0.05, and "**" indicates p<0.01, which are significantly different compared with the 10% FBS group.

[0028] Figure 5 The osteogenic medium containing 2×CGF induced the mRNA expression of osteogenic markers RUNX2, COL1α1 and OCN in SHED on days 7 and 14; "*" indicates p<0.05, and "**" indicates p<0.01, which are significantly different compared with 10% FBS.

[0029] Figure 6 Figures 2A and 2B show the results of cell surface markers of SHED after culture in 5% HS in the presence or absence of 2×CGF (A) and the results of karyotype analysis of SHED at passage 3 cultured with 10% FBS, 5% HS and 2×CGF for 3 days (B).

[0030] Figure 7 SHED showed multi-lineage differentiation ability under different culture conditions; A is the Alizarin red staining result of SHED after inducing osteogenic differentiation, B is the calcium blue staining result of SHED after chondrogenic differentiation, and C is the Oil Red O staining result of SHED after adipogenic differentiation. DETAILED DESCRIPTION

[0031] The present invention is further described below in conjunction with the accompanying drawings and specific examples, but the examples do not limit the present invention in any form. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art.

[0032] Unless otherwise specified, the reagents and materials used in the following examples are commercially available.

[0033] Example 1

[0034] Preparation of a heterologous serum / exogenous growth factor-free culture system containing CGF and HS:

[0035] The inclusion criteria for concentrated growth factor (CGF) and human serum (HS) donation were: 1) age: 20-30 years old; 2) non-smokers; 3) healthy and free of infectious diseases; 4) free of blood diseases and normal platelet count; 5) no medication that affects platelet function within 3 months before blood collection. All donors signed informed consent.

[0036] Venous blood was collected and immediately centrifuged in Medifuge MF200 to obtain three layers, from top to bottom, including serum layer, gelatinous CGF layer and red blood cell layer. The serum in the upper layer was collected and stored in a refrigerator at -80 degrees Celsius for later use. The CGF in the middle layer was pressed with sterile gauze to absorb excess liquid, so that the gelatinous CGF became a membrane structure, called "CGF membrane". This membrane was freeze-dried in a vacuum freeze dryer overnight and ground into CGF powder using a planetary ball mill. The obtained CGF powder was suspended in 50 ml of culture medium and incubated at 4°C for 24 hours. The suspension was centrifuged at 453×g for 5 minutes to separate red blood cells from the culture medium. Finally, the culture medium containing CGF was collected and 5% HS and 1% antibiotics were added.

[0037] The concentration of CGF was defined as follows: 1×CGF represented CGF extracted from 10 mL of venous blood and placed in 50 mL of culture medium; or 1×CGF was approximately 0.05 g of freeze-dried CGF dissolved in 50 mL of culture medium.

[0038] Using DMEM-high glucose as the basic culture medium, adding corresponding HS, CGF and antibiotics, a heterologous serum / exogenous growth factor-free culture system containing CGF and HS was constructed.

[0039] Example 2

[0040] Extraction and identification of SHED:

[0041] All deciduous teeth were collected from children in the Department of Pediatric Stomatology, Affiliated Hospital of Stomatology, Guangzhou Medical University. The inclusion criteria for deciduous tooth collection were: 1) children aged 6 to 8 years; 2) the root resorption rate of deciduous teeth was less than 1 / 3; 3) no caries, no periapical disease; 4) the child donor had no history of systemic and genetic diseases. The Ethics Committee of the Affiliated Hospital of Stomatology, Guangzhou Medical University provided ethical approval for the use of SHEDs (No. LCYJ2021025). Informed consent was obtained from the parents / guardians of the children who donated deciduous teeth. SHEDs isolated from the pulp of children's deciduous teeth were grown and maintained at 37°C in DMEM-high glucose medium supplemented with 10% FBS and 1% penicillin-streptomycin. SHED surface markers were detected by flow cytometry, and SHED was identified as deciduous dental pulp stem cells with osteogenic and adipogenic differentiation multidirectional differentiation ability. SHEDs of the 3rd to 5th generations were used in all experiments of the present invention. First, the effects of HS and CGF on the proliferation, clone formation and migration ability of SHED were explored:

[0042] 1. Effects of HS and CGF on SHED proliferation ability:

[0043] Control group: DMEM+10% FBS+1% penicillin-streptomycin; DMEM+5% HS+1% penicillin-streptomycin;

[0044] Experimental groups: DMEM+5% HS+1% penicillin-streptomycin+CGF (2×, 4× or 8×).

[0045] SHED was performed at 1 × 10 per well of a 96-well plate. 3 Cells were inoculated and cultured for 1, 3, 5, and 7 days. The total number of cells was determined using a cell counting kit-8 (CCK-8; Dojindo, Kumamoto, Japan). The optical density was measured at 450 nm using a microplate reader. Three independent experiments were repeated.

[0046] 2. Detect the effect of CGF on SHED clone formation ability:

[0047] Positive control group: DMEM + 10% FBS + 1% penicillin-streptomycin;

[0048] Negative control group: DMEM+5% HS+1% penicillin-streptomycin;

[0049] Experimental group: DMEM+5% HS+1% penicillin-streptomycin+CGF.

[0050] SHED was seeded with 100 cells per well of a 6-well plate and cultured for 10 consecutive days without changing the medium to determine the SHED clone formation ability. SHED colonies were stained with crystal violet and counted visually. SHED colonies with a diameter greater than 1 mm were identified as one colony unit. The experiment was repeated three times independently.

[0051] 3. Detect the effect of CGF on SHED migration ability:

[0052] 1) Transwell cell migration assay

[0053] Transwell migration assay was used to evaluate the effect of CGF on the three-dimensional (3D) migration ability of SHED.

[0054] Positive control group: DMEM + 10% FBS + 1% penicillin-streptomycin;

[0055] Negative control group: DMEM+5% HS+1% penicillin-streptomycin;

[0056] Experimental group: DMEM+5% HS+1% penicillin-streptomycin+CGF.

[0057] The experiment was performed using a 24-well transwell chamber. 4 SHED / 200μL serum-free medium was added to the upper chamber, 600μL complete medium containing 10% FBS, and 5% HS complete medium with or without CGF was added to the lower chamber and incubated at 37°C for 24h. The migrated SHED were fixed with 4% paraformaldehyde for 30min, washed with deionized water, stained with crystal violet, and washed again with deionized water. The cells inside the upper chamber were gently wiped with a cotton swab to prevent counting errors. The lens was moved at 10× magnification, and 6 microscope fields were randomly selected to count the migrated cells. Make sure to use the same field selection strategy for each repeated experiment. The number of cells per field was calculated using ImageJ software, and the average number of cells per field was determined using GraphPad Prism 9.0.2 software.

[0058] 2) Scratch test

[0059] The scratch assay was used to evaluate the effect of CGF on the planar migration of SHED.

[0060] Positive control group: DMEM + 10% FBS + 1% penicillin-streptomycin;

[0061] Negative control group: DMEM+5% HS+1% penicillin-streptomycin;

[0062] Experimental group: DMEM+5% HS+1% penicillin-streptomycin+CGF.

[0063] SHED was cultured in 6-well plates until cell confluence reached 90%. Scratches were made using sterile plastic 200 μL micropipette tips. After washing with PBS, the culture medium containing 2% FBS, 1% HS and 1% HS+CGF was replaced respectively. Photos of the scratch area were taken at 0, 6, 12 and 24 h using a 10x optical upright microscope. Make sure that photos are taken and measured from the same scratch position at each time point. The scratch area was evaluated using ImageJ software. Scratching recovery rate (%) = (original scratch area - scratch area at metering point) / original scratch area × 100%.

[0064] The results are as follows:

[0065] Effect of 5% HS+CGF on the proliferation ability of SHED ( Figure 1 ): No cytotoxic effect was observed at different concentrations of CGF (2×, 4× and 8×), and all concentrations of CGF had a positive effect on the proliferation of SHED. In the control group, 5% HS was slightly better than 10% FBS in promoting SHED proliferation on the 3rd day, and slightly lower than 10% FBS on the 5th and 7th days, but there was no significant difference. CGF (2×, 4× and 8×) combined with 5% HS can show the same effect of promoting SHED proliferation as 10% FBS. CGF (2×, 4× and 8×) combined with 5% HS showed a stronger proliferation-promoting effect on the 5th and 7th days than 5% HS alone (p<0.05). It is worth noting that compared with 2×CGF, 4× and 8× concentrations of CGF did not show a stronger proliferation effect.

[0066] Effect of 5% HS+CGF on SHED clone formation ability: Results are as follows Figure 2 Each bar represents the mean ± SD of CFU from three independent experiments. Two SHED batches were analyzed by independent t-test. Colony morphology (A) and colony number (B) of SHED cultured under the conditions of 10% FBS, 5% HS or 5% HS + 2×CGF are shown in Figure 2. Figure 3 As shown, the SHED colonies formed in the presence of 5% HS + 2×CGF were denser and larger on day 10, and the number of colonies was not statistically different from that of the positive control group, while there was no statistical difference between the negative control group and the positive control group.

[0067] Effect of 5% HS+CGF on SHED migration ability ( Figure 3 ): Transwell experiment results show ( Figure 3A, B), after 24h of culture, the density of migrating cells in the 2×CGF group was significantly higher than that in the negative control group (2.3 times; p<0.0001) and the positive control group (1.6 times; p<0.0001). The scratch test results showed that ( Figure 3 C, D), after 24h of culture, the scratch area in the 2×CGF group was significantly reduced compared with the negative control group (1.5 times; p<0.0001). Therefore, the results showed that 5% HS + 2×CGF can effectively promote the horizontal and vertical migration of SHED.

[0068] In summary, in the culture of SHED, replacing 10% FBS with 5% HS or 5% HS+CGF had no effect on the proliferation and clone formation ability of SHED, while 5% HS+2×CGF could significantly enhance the migration ability of SHED.

[0069] Example 3

[0070] 1. Detection of the effect of CGF on the osteogenic differentiation potential of SHED

[0071] Positive control group: DMEM + 10% FBS + 1% penicillin-streptomycin + 10 nM dexamethasone + 10 mM β-glycerophosphate + 50 μg / mL ascorbic acid;

[0072] Negative control group: DMEM + 5% HS + 1% penicillin-streptomycin + 10 nM dexamethasone + 10 mM β-glycerophosphate + 50 μg / mL ascorbic acid;

[0073] Experimental group: DMEM+5% HS+1% penicillin-streptomycin+10 nM dexamethasone+10 mM β-glycerophosphate+50 μg / mL ascorbic acid+CGF.

[0074] 1) Alkaline phosphatase staining (ALP)

[0075] Alkaline phosphatase (ALP) protein staining was used to evaluate the osteogenic phenotype of SHED cultured for 4 and 7 days.

[0076] SHED were seeded in 48-well culture plates at 2.0 × 10 4 Cells were cultured in osteogenic induction medium with or without CGF in 5% HS for 4 and 7 days, and the medium was changed every 3 days. For ALP staining, cells were fixed in 4% paraformaldehyde for 30 min, washed three times with deionized water, and stained with 5-bromo-4-chloro-3-indolyl phosphate / nitro blue tetrazolium (BCIP / NBT) ALP colorimetric kit. The entire well was observed and photographed at a magnification of 0.82 times using a stereo microscope. The optical density of the stained ALP protein was measured using ImageJ software to semi-quantitate ALP protein.

[0077] 2) RNA isolation and real-time quantitative PCR (RT-qPCR) analysis

[0078] SHEDs were cultured in osteogenic induction medium supplemented with 10% FBS and 5% HS with or without CGF for 7 or 14 days. Total RNA of SHEDs was extracted using an RNA extraction kit and reverse transcribed. Premix Ex Taq TM II was used to detect the relative mRNA expression of target genes (ALP, RUNX2, COL1α1 and OCN). Glyceraldehyde phosphate dehydrogenase (GAPDH) was used to normalize the mRNA expression level.

[0079] 2. Detection of the effect of CGF on SHED surface markers and karyotype analysis

[0080] Control group: DMEM+5% HS+1% penicillin-streptomycin;

[0081] Experimental group: DMEM+5% HS+1% penicillin-streptomycin+CGF.

[0082] Flow cytometry was used to determine whether CGF affects SHED phenotype (CD90, CD73, CD105, CD14, CD34, and HLA-DR). Karyotyping was performed to determine the possible effects of CGF on stem cell karyotype.

[0083] The cell samples (5.0×10 5 Cells / mL) were incubated with CD90-PE-CY5, CD73-FITC, CD105-PE, CD14-FITC, CD34-PE and HLA-DR-FITC at 4°C for 30 minutes. After incubation, the cells were washed and suspended in PBS. Flow cytometry was used to analyze the cell surface expression of CD90, CD73, CD105, CD14, CD34 and HLA-DR markers.

[0084] SHEDs were cultured in medium supplemented with 10% FBS, 5% HS and 2×CGF for 72 h. SHED samples were then sent to a biological company for karyotype analysis.

[0085] 3. Detection of the effect of CGF on the multidirectional differentiation potential of SHED

[0086] Positive control group: DMEM + 10% FBS + 1% penicillin-streptomycin;

[0087] Negative control group: DMEM+5% HS+1% penicillin-streptomycin;

[0088] Experimental group: DMEM+5% HS+1% penicillin-streptomycin+CGF.

[0089] 1) Osteogenic differentiation (detection of mineralized nodules, using Alizarin red staining)

[0090] SHED was placed in each well of a 48-well plate at 2.5 × 10 4 Cells were seeded at 4% 4% PBS. When the cell confluence reached 80-90%, the medium was changed to osteogenic differentiation medium. The medium was changed every 3 days for 21 days. To detect mineralization, the cells were fixed in 4% formaldehyde for 30 minutes. The cells were then washed with deionized water and stained with 0.5% Alizarin Red S staining solution for 5 minutes at room temperature. Images were acquired using a stereomicroscope.

[0091] 2) Chondrogenic differentiation (detection of cartilage sulfate mannan using Alcian blue staining)

[0092] 1×10 5 10 μL of SHED suspension was dropped into a 48-well plate, and after standing for 2 hours, SHED formed cell microclusters, and then cultured in DMEM-high glucose medium containing 10% FBS, 1% penicillin and streptomycin for 1 day. Then, the human bone marrow mesenchymal stem cell chondrogenic differentiation kit was used to induce chondrogenic differentiation for 14 days, and the culture medium was changed every 3 days. Subsequently, the microclusters were fixed in 4% glutaraldehyde for 30 minutes and stained with Alcian blue. The staining depth was evaluated by microscopic photos (8×) to determine the concentration of glycosyl glycans.

[0093] 2) Adipogenic differentiation (detection of intracellular lipid droplets, using red oil O staining)

[0094] SHED were seeded into 6-well plates and cultured using the Human Stem Cell Adipogenic Differentiation Kit. The cells were fixed with 4% paraformaldehyde for 30 min at room temperature. After washing with PBS, they were stained with Oil Red O for 30 min. The cells were photographed with a 20x magnifying glass to evaluate intracellular lipid droplets.

[0095] The results are as follows:

[0096] Detection of the effect of CGF on the osteogenic differentiation potential of SHED ( Figure 4 , 5): ALP staining and quantification of SHED were performed on days 4 and 7, and the results are expressed as the mean ± SD of three measurements from three independent experiments. ALP staining ( Figure 4 A) and semi-quantitative experiments ( Figure 4B) The results showed that the effect of 5% HS group on stimulating SHED to produce ALP on the 7th day was significantly better than that of 10% FBS group, indicating that compared with 10% FBS, 5% HS significantly increased the osteogenic differentiation potential of SHED; compared with 10% FBS group and 5% HS group, osteogenic medium containing CGF (2×, 4×, 8×) stimulated SHED to produce ALP on the 4th and 7th days, indicating that the addition of CGF can significantly increase the osteogenic differentiation potential of SHED. The results of osteogenesis-related mRNA expression showed ( Figure 5 ), the relative gene expression levels were expressed as the mean ± SD of three measurements from three independent experiments. Compared with the 10% FBS group, the 5% HS group increased the mRNA expression of the early osteogenic marker COL1α1 in SHED on day 7; compared with the 10% FBS group and the 5% HS group, the osteogenic medium containing 2×CGF induced a significant increase in the mRNA expression of the early osteogenic markers RUNX2 and COL1α1 in SHED on days 7 and 14, and induced a significant increase in the mRNA expression of the late osteogenic marker OCN on day 14.

[0097] Detection of the effect of CGF on SHED surface markers and karyotype analysis: Figure 6 A is flow cytometry detection of cell surface markers after SHED was cultured in 5% HS with or without 2×CGF; Figure 6 B is the karyotype analysis of the third generation SHED cultured with 10% FBS and 5% HS containing 2×CGF for 3 days. The results showed that under the culture conditions with CGF, the expression of SHED surface markers was stable and the chromosome karyotype was normal.

[0098] Detection of the effect of CGF on the multi-lineage differentiation potential of SHED: SHED showed multi-lineage differentiation ability under different culture conditions. Figure 7 The results of Alizarin Red (A), Cartilage Blue (B) and Oil Red O (C) staining after SHED induced osteogenic, chondrogenic and adipogenic differentiation. The results showed that SHED had multidirectional differentiation potentials of osteogenic, chondrogenic and adipogenic differentiation under the culture conditions of CGF. In summary, CGF does not affect the stem cell characteristics of SHED.

Claims

1. A fetal bovine serum-free culture system for deciduous dental pulp stem cells, characterized in that: The method comprises a basic culture medium and additional components; the additional components are 4.5-5.5% human serum and 0.002-0.008 g / mL concentrated growth factor accounting for 4.5-5.5% of the volume fraction of the basic culture medium.

2. The deciduous tooth dental pulp stem cell culture system according to claim 1, characterized in that: The added components are 5% human serum and 0.002-0.008 g / mL concentrated growth factor accounting for 5% of the volume fraction of the basic culture medium.

3. The deciduous tooth dental pulp stem cell culture system according to claim 1, characterized in that: The basic culture medium is DMEM-high glucose culture medium.

4. The deciduous tooth dental pulp stem cell culture system according to claim 1, characterized in that: Also contains antibiotics.

5. The deciduous tooth dental pulp stem cell culture system according to claim 4, characterized in that: The antibiotics are penicillin and / or streptomycin.

6. Use of the deciduous tooth dental pulp stem cell culture system according to any one of claims 1 to 5 in the in vitro proliferation of deciduous tooth dental pulp stem cells.

7. Use of the deciduous tooth dental pulp stem cell culture system according to any one of claims 1 to 5 in inducing differentiation of deciduous tooth dental pulp stem cells in vitro.

8. The use according to claim 7, characterized in that: The differentiation is one or more of osteogenic differentiation, adipogenic differentiation or chondrogenic differentiation.

9. A method for culturing deciduous tooth dental pulp stem cells, characterized in that: The deciduous tooth dental pulp stem cells are cultured using the culture system of any one of claims 1 to 5.

10. The method according to claim 9, characterized in that: The culture is proliferation culture or differentiation induction culture.

Citation Information

Patent Citations

  • Serum-free culture medium for human periodontal ligament stem cells

    CN112795532A

  • Preparation for promoting hair growth and preparation method thereof

    CN113750116A

  • Method for manufacturing peach red pepper paste comprising peach concentrate

    KR1020250074499A

  • Modulation of cardiac stem-progenitor cell differentiation, assays and uses thereof

    US20150368618A1